Jazz Pharmaceuticals PLC Company Profile (NASDAQ:JAZZ)

About Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Jazz Pharmaceuticals PLC logoJazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder. Its marketed products and late-stage product candidate are Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) Extended-Release Capsules and JZP-6 (sodium oxybate). Its other product candidates in clinical development are oral tablet forms of sodium oxybate; JZP-8 (intranasal clonazepam); JZP-4 (elpetrigine), and JZP-7 (ropinirole gel).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:JAZZ
  • CUSIP: G5087110
  • Web: www.jazzpharma.com
Capitalization:
  • Market Cap: $8.85741 billion
  • Outstanding Shares: 60,091,000
Average Prices:
  • 50 Day Moving Avg: $153.65
  • 200 Day Moving Avg: $147.43
  • 52 Week Range: $95.80 - $163.75
P/E:
  • Trailing P/E Ratio: 22.49
  • Foreward P/E Ratio: 12.98
  • P/E Growth: 0.81
Sales & Book Value:
  • Annual Revenue: $1.54 billion
  • Price / Sales: 5.70
  • Book Value: $36.64 per share
  • Price / Book: 3.98
Profitability:
  • EBIDTA: $758.97 million
  • Net Margins: 25.69%
  • Return on Equity: 22.75%
  • Return on Assets: 9.14%
Debt:
  • Debt-to-Equity Ratio: 0.74%
  • Current Ratio: 2.65%
  • Quick Ratio: 2.49%
Misc:
  • Average Volume: 463,219 shs.
  • Beta: 1.1
  • Short Ratio: 3.05
 

Frequently Asked Questions for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

What is Jazz Pharmaceuticals PLC's stock symbol?

Jazz Pharmaceuticals PLC trades on the NASDAQ under the ticker symbol "JAZZ."

How were Jazz Pharmaceuticals PLC's earnings last quarter?

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) announced its quarterly earnings data on Tuesday, August, 8th. The company reported $1.72 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $1.85 by $0.13. The company had revenue of $394.39 million for the quarter, compared to the consensus estimate of $410.83 million. Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 22.75%. The company's revenue was up 3.5% compared to the same quarter last year. During the same quarter last year, the firm posted $2.67 earnings per share. View Jazz Pharmaceuticals PLC's Earnings History.

When will Jazz Pharmaceuticals PLC make its next earnings announcement?

Jazz Pharmaceuticals PLC is scheduled to release their next quarterly earnings announcement on Tuesday, November, 14th 2017. View Earnings Estimates for Jazz Pharmaceuticals PLC.

What guidance has Jazz Pharmaceuticals PLC issued on next quarter's earnings?

Jazz Pharmaceuticals PLC issued an update on its FY17 earnings guidance on Tuesday, August, 8th. The company provided EPS guidance of $10.70-11.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $11.02. The company issued revenue guidance of $1.625-1.7 billion, compared to the consensus revenue estimate of $1.66 billion.

Where is Jazz Pharmaceuticals PLC's stock going? Where will Jazz Pharmaceuticals PLC's stock price be in 2017?

18 brokerages have issued 12 month target prices for Jazz Pharmaceuticals PLC's shares. Their forecasts range from $150.00 to $210.00. On average, they expect Jazz Pharmaceuticals PLC's stock price to reach $185.00 in the next twelve months. View Analyst Ratings for Jazz Pharmaceuticals PLC.

What are analysts saying about Jazz Pharmaceuticals PLC stock?

Here are some recent quotes from research analysts about Jazz Pharmaceuticals PLC stock:

  • 1. According to Zacks Investment Research, "Jazz’s largest franchise is its sleep disorder portfolio. The company’s sleep disorder drug, Xyrem, is the only FDA-approved product for both cataplexy and EDS. Its lead pipeline candidate, JZP-110, being developed for the treatment of EDS in patients suffering from narcolepsy and OSA, complements its existing sleep disorder portfolio. Moreover, In Oct 2016, Jazz commenced a rolling submission for its second pipeline candidate, Vyxeos, which was completed in early Apr 2017. Jazz’ shares outperformed the industry so far this year. However, Xyrem is facing patent challenges. Jazz has also been facing challenges in building sufficient inventory levels for leukemia drug Erwinaze due to constrained manufacturing capacity and may experience further supply disruptions this year. Estimates have been stable lately ahead of the company’s Q2 earnings release." (8/8/2017)
  • 2. Cantor Fitzgerald analysts commented, "Meetings highlight view that late-stage assets are underappreciated. We hosted meetings with the CEO in the Midwest last week. Investors he met with expressed interest in Xyrem, of course, but the bulk of the questions centered around the pipeline. A common theme was that JZP-110 may be underestimated by the Street. We also spoke with some investors who seem to be gaining appreciation for the potential of the low-sodium oxybate formulations. Vyxeos approval could be around the corner. The PDUFA date for Vyxeos is September 30, and management commented that Breakthrough-designated drugs have been approved before the statutory date." (6/27/2017)
  • 3. Mizuho analysts commented, "We raise our PT to $162 from $152 while reiterating our Buy rating following positive Phase III data in a key pipeline drug (JZP-110) in obstructive sleep apnea. Our PT went up due to increased likelihood of FDA approval." (3/21/2017)
  • 4. Cowen and Company analysts commented, "complete re-rating."Cacciatore comments, "We continue to believe Jazz is nearing a very interesting inflection point, as a favorable resolution to the Xyrem litigation is likely, which could extend the franchise to 2024/2025. Combined with JZP-110's potential $750MM+ opportunity to complement growing Defitelio, Erwinaze, and ultimately Vyxeos, we believe a complete re-rating is nearing. We would add here." (3/20/2017)
  • 5. BMO Capital Markets analysts commented, "JAZZ delivered on an important milestone with positive Phase 3 data for JZP-110 in two OSA studies that appear to demonstrate a very solid clinical profile for this novel wake-promoting agent. There had been some concerns into these data (first OSA studies for JZP-110), and we think this outcome significantly de-risks the program; Phase 3 data in narcolepsy set for 2Q17 and filing in late 2017. We reiterate our Outperform; JAZZ remains a top pick." (3/20/2017)

Who are some of Jazz Pharmaceuticals PLC's key competitors?

Who owns Jazz Pharmaceuticals PLC stock?

Jazz Pharmaceuticals PLC's stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (13.81%), Vanguard Group Inc. (7.79%), BlackRock Inc. (5.18%), JPMorgan Chase & Co. (2.34%), Bank of New York Mellon Corp (2.30%) and Westfield Capital Management Co. LP (2.20%). Company insiders that own Jazz Pharmaceuticals PLC stock include Bruce C Cozadd, Heather Ann Mcsharry, Karen J Wilson, Karen L Smith, Kenneth W O'keefe, Michael Patrick Miller, Patrick G Enright, Paul L Berns, Paul Treacy, Rick E Winningham, Russell J Cox, Seamus Mulligan and Suzanne Sawochka Hooper. View Institutional Ownership Trends for Jazz Pharmaceuticals PLC.

Who sold Jazz Pharmaceuticals PLC stock? Who is selling Jazz Pharmaceuticals PLC stock?

Jazz Pharmaceuticals PLC's stock was sold by a variety of institutional investors in the last quarter, including FIL Ltd, BlackRock Inc., Nomura Holdings Inc., Bank of New York Mellon Corp, Tekla Capital Management LLC, Westfield Capital Management Co. LP, Gateway Investment Advisers LLC and State Street Corp. Company insiders that have sold Jazz Pharmaceuticals PLC stock in the last year include Bruce C Cozadd, Karen J Wilson, Michael Patrick Miller, Patrick G Enright, Paul L Berns, Paul Treacy, Rick E Winningham, Russell J Cox, Seamus Mulligan and Suzanne Sawochka Hooper. View Insider Buying and Selling for Jazz Pharmaceuticals PLC.

Who bought Jazz Pharmaceuticals PLC stock? Who is buying Jazz Pharmaceuticals PLC stock?

Jazz Pharmaceuticals PLC's stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, FMR LLC, JPMorgan Chase & Co., American Century Companies Inc., Zurcher Kantonalbank Zurich Cantonalbank, Balyasny Asset Management LLC, Vanguard Group Inc. and Pioneer Investment Management Inc.. Company insiders that have bought Jazz Pharmaceuticals PLC stock in the last two years include Karen L Smith and Kenneth W O'keefe. View Insider Buying and Selling for Jazz Pharmaceuticals PLC.

How do I buy Jazz Pharmaceuticals PLC stock?

Shares of Jazz Pharmaceuticals PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Jazz Pharmaceuticals PLC's stock price today?

One share of Jazz Pharmaceuticals PLC stock can currently be purchased for approximately $146.01.


MarketBeat Community Rating for Jazz Pharmaceuticals PLC (NASDAQ JAZZ)
Community Ranking:  3.8 out of 5 (  )
Outperform Votes:  653 (Vote Outperform)
Underperform Votes:  198 (Vote Underperform)
Total Votes:  851
MarketBeat's community ratings are surveys of what our community members think about Jazz Pharmaceuticals PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 16 Buy Ratings
Consensus Rating:Buy (Score: 2.89)
Consensus Price Target: $185.00 (26.70% upside)

Analysts' Ratings History for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/10/2017Piper Jaffray CompaniesReiterated RatingBuy$177.00LowView Rating Details
8/10/2017Wells Fargo & CompanyReiterated RatingOutperform$178.00 -> $177.00LowView Rating Details
8/9/2017Cowen and CompanyReiterated RatingOutperform$190.00LowView Rating Details
8/9/2017Deutsche Bank AGSet Price TargetBuy$178.00 -> $175.00HighView Rating Details
8/9/2017Royal Bank Of CanadaReiterated RatingBuyLowView Rating Details
8/9/2017Janney Montgomery ScottReiterated RatingBuy$180.00 -> $192.00LowView Rating Details
7/4/2017MizuhoDowngradeBuy -> Neutral$162.00 -> $150.00LowView Rating Details
7/4/2017Leerink SwannBoost Price TargetBuy$169.00 -> $170.00LowView Rating Details
6/27/2017Cantor FitzgeraldReiterated RatingBuy$197.00MediumView Rating Details
6/12/2017J P Morgan Chase & CoReiterated RatingOverweight$190.00LowView Rating Details
6/7/2017BMO Capital MarketsBoost Price TargetOutperform$192.00 -> $196.00MediumView Rating Details
5/22/2017Sanford C. BernsteinSet Price TargetMarket Perform$160.00 -> $176.00LowView Rating Details
3/1/2017Stifel NicolausLower Price TargetBuy$200.00 -> $190.00N/AView Rating Details
2/22/2017Evercore ISIInitiated CoverageBuy$160.00N/AView Rating Details
2/16/2017GuggenheimReiterated RatingBuyN/AView Rating Details
1/19/2017SunTrust Banks, Inc.Reiterated RatingBuy$210.00N/AView Rating Details
1/18/2017Goldman Sachs Group, Inc. (The)Reiterated RatingBuy$170.00N/AView Rating Details
1/18/2017Barclays PLCReiterated RatingOverweight$200.00N/AView Rating Details
4/5/2016Canaccord GenuityReiterated RatingBuy$170.00N/AView Rating Details
4/1/2016Northland SecuritiesReiterated RatingOutperform$175.00N/AView Rating Details
(Data available from 8/18/2015 forward)

Earnings

Earnings History for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Earnings by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Earnings History by Quarter for Jazz Pharmaceuticals PLC (NASDAQ JAZZ)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2017        
8/8/20176/30/2017$1.85$1.72$410.83 million$394.39 millionViewListenView Earnings Details
5/9/20173/31/2017$1.42$1.41$376.58 million$376.10 millionViewListenView Earnings Details
2/28/2017Q416$2.65$1.91$398.91 million$396.62 millionViewListenView Earnings Details
11/8/2016Q316$2.61$2.16$389.34 million$374.00 millionViewListenView Earnings Details
8/9/2016Q216$2.80$2.63$376.40 million$381.00 millionViewN/AView Earnings Details
5/10/2016Q1$2.31$2.26$338.86 million$336.00 millionViewListenView Earnings Details
2/23/2016Q415$2.60$2.60$349.98 million$340.90 millionViewListenView Earnings Details
11/9/2015Q315$2.56$2.52$348.15 million$340.90 millionViewListenView Earnings Details
8/5/2015Q215$2.41$2.41$335.58 million$333.70 millionViewListenView Earnings Details
5/7/2015Q115$2.15$1.99$309.50 million$309.30 millionViewListenView Earnings Details
2/24/2015Q414$2.30$2.44$319.74 million$328.10 millionViewListenView Earnings Details
11/4/2014Q314$1.98$2.33$302.90 million$306.58 millionViewListenView Earnings Details
8/5/2014Q214$1.92$2.05$273.39 million$291.23 millionViewListenView Earnings Details
5/8/2014Q114$1.79$1.61$254.86 million$247.00 millionViewListenView Earnings Details
2/25/2014Q413$1.78$1.72$238.12 million$235.80 millionViewListenView Earnings Details
11/5/2013Q313$1.67$1.78$227.38 million$232.20 millionViewListenView Earnings Details
8/6/2013Q2 2013$1.52$1.43$208.71 million$208.30 millionViewListenView Earnings Details
5/7/2013Q1 2013$1.35$1.37$189.92 million$196.20 millionViewListenView Earnings Details
2/26/2013Q4 2012$1.41$1.53$183.80 million$183.70 millionViewListenView Earnings Details
11/8/2012Q312$1.31$1.29$178.57 million$175.50 millionViewN/AView Earnings Details
8/7/2012$1.05$1.09ViewN/AView Earnings Details
5/8/2012$0.90$0.91ViewN/AView Earnings Details
11/1/2011$0.89$0.94ViewN/AView Earnings Details
7/28/2011$0.67$0.82ViewN/AView Earnings Details
5/3/2011$0.57$0.59ViewN/AView Earnings Details
3/7/2011$0.60$0.63ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20172$1.89$2.84$2.37
Q3 20172$1.98$2.47$2.23
Q4 20172$2.17$2.78$2.48
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Insider Ownership Percentage: 4.30%
Institutional Ownership Percentage: 87.22%
Insider Trades by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Institutional Ownership by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Insider Trades by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/15/2017Michael Patrick MillerEVPSell200$144.38$28,876.00View SEC Filing  
8/14/2017Paul TreacySVPSell1,304$143.32$186,889.28View SEC Filing  
8/11/2017Paul L BernsDirectorSell662$142.37$94,248.94View SEC Filing  
7/20/2017Suzanne Sawochka HooperEVPSell4,580$160.00$732,800.00View SEC Filing  
7/17/2017Michael Patrick MillerEVPSell200$154.97$30,994.00View SEC Filing  
6/23/2017Suzanne Sawochka HooperEVPSell420$160.00$67,200.00View SEC Filing  
6/15/2017Michael Patrick MillerEVPSell200$150.65$30,130.00View SEC Filing  
6/1/2017Rick E WinninghamDirectorSell5,000$150.00$750,000.00View SEC Filing  
5/15/2017Michael Patrick MillerEVPSell200$152.98$30,596.00View SEC Filing  
5/11/2017Bruce C CozaddCEOSell30,000$153.47$4,604,100.00View SEC Filing  
5/9/2017Suzanne Sawochka HooperEVPSell2,500$160.00$400,000.00View SEC Filing  
4/27/2017Karen J WilsonSVPSell1,275$160.00$204,000.00View SEC Filing  
4/27/2017Suzanne Sawochka HooperEVPSell2,500$160.00$400,000.00View SEC Filing  
4/17/2017Michael Patrick MillerSVPSell200$152.56$30,512.00View SEC Filing  
4/11/2017Bruce C CozaddCEOSell1,000$152.12$152,120.00View SEC Filing  
4/10/2017Karen J WilsonSVPSell11,458$152.24$1,744,365.92View SEC Filing  
3/15/2017Michael Patrick MillerSVPSell200$137.89$27,578.00View SEC Filing  
3/6/2017Paul TreacySVPSell884$131.97$116,661.48View SEC Filing  
2/15/2017Michael Patrick MillerSVPSell200$134.55$26,910.00View SEC Filing  
1/18/2017Russell J. CoxCOOSell4,000$128.75$515,000.00View SEC Filing  
1/17/2017Michael Patrick MillerSVPSell200$115.93$23,186.00View SEC Filing  
12/15/2016Michael Patrick MillerSVPSell200$103.09$20,618.00View SEC Filing  
12/2/2016Patrick G EnrightDirectorSell677$101.80$68,918.60View SEC Filing  
11/15/2016Michael Patrick MillerSVPSell200$112.19$22,438.00View SEC Filing  
11/14/2016Kenneth W O'keefeDirectorBuy2,000$113.84$227,680.00View SEC Filing  
10/17/2016Michael Patrick MillerSVPSell200$118.16$23,632.00View SEC Filing  
9/19/2016Michael Patrick MillerSVPSell200$126.17$25,234.00View SEC Filing  
8/25/2016Seamus MulliganDirectorSell27,968$128.32$3,588,853.76View SEC Filing  
8/16/2016Paul TreacySVPSell1,292$137.47$177,611.24View SEC Filing  
8/15/2016Michael Patrick MillerSVPSell100$136.45$13,645.00View SEC Filing  
8/15/2016Rick E WinninghamDirectorSell633$136.45$86,372.85View SEC Filing  
8/12/2016Karen L SmithInsiderBuy608$137.10$83,356.80View SEC Filing  
8/9/2016Bruce C. CozaddCEOSell1,000$150.00$150,000.00View SEC Filing  
8/9/2016Russell J. CoxCOOSell4,000$148.66$594,640.00View SEC Filing  
7/15/2016Michael Patrick MillerSVPSell100$142.43$14,243.00View SEC Filing  
7/13/2016Karen L SmithCMOBuy580$143.63$83,305.40View SEC Filing  
6/15/2016Michael Patrick MillerSVPSell100$149.64$14,964.00View SEC Filing  
6/13/2016Karen L SmithCMOBuy557$149.61$83,332.77View SEC Filing  
5/16/2016Heather Ann McsharryDirectorSell697$145.20$101,204.40View SEC Filing  
5/16/2016Michael Patrick MillerSVPSell100$145.20$14,520.00View SEC Filing  
4/25/2016Karen J WilsonSVPSell604$160.00$96,640.00View SEC Filing  
4/15/2016Michael Patrick MillerSVPSell100$145.79$14,579.00View SEC Filing  
4/13/2016Karen J WilsonSVPSell5,007$150.00$751,050.00View SEC Filing  
4/12/2016Russell J CoxCOOSell4,000$136.98$547,920.00View SEC Filing  
4/7/2016Karen J WilsonSVPSell2,161$140.90$304,484.90View SEC Filing  
3/15/2016Michael Patrick MillerSVPSell100$129.17$12,917.00View SEC Filing  
3/8/2016Bruce C CozaddCEOSell2,500$126.04$315,100.00View SEC Filing  
2/29/2016Paul TreacySVPSell354$123.48$43,711.92View SEC Filing  
2/23/2016Seamus MulliganDirectorSell27,968$122.71$3,431,953.28View SEC Filing  
2/16/2016Michael Patrick MillerSVPSell100$115.63$11,563.00View SEC Filing  
2/10/2016Patrick G EnrightDirectorSell10,000$117.92$1,179,200.00View SEC Filing  
2/9/2016Bruce C CozaddCEOSell2,500$111.37$278,425.00View SEC Filing  
1/15/2016Michael Patrick MillerSVPSell100$122.66$12,266.00View SEC Filing  
1/12/2016Bruce C CozaddCEOSell2,500$123.81$309,525.00View SEC Filing  
1/5/2016Patrick G EnrightDirectorSell10,000$138.09$1,380,900.00View SEC Filing  
12/15/2015Michael Patrick MillerSVPSell100$136.99$13,699.00View SEC Filing  
12/8/2015Bruce C CozaddCEOSell2,500$139.72$349,300.00View SEC Filing  
12/2/2015Patrick G EnrightDirectorSell10,424$146.67$1,528,888.08View SEC Filing  
11/23/2015Seamus MulliganDirectorSell27,968$145.86$4,079,412.48View SEC Filing  
11/10/2015Bruce C CozaddCEOSell2,500$128.53$321,325.00View SEC Filing  
11/10/2015Patrick G EnrightDirectorSell10,000$135.29$1,352,900.00View SEC Filing  
10/21/2015Suzanne Sawochka HooperEVPSell2,000$125.00$250,000.00View SEC Filing  
10/13/2015Bruce C CozaddCEOSell2,500$131.50$328,750.00View SEC Filing  
10/5/2015Patrick G EnrightDirectorSell10,000$133.79$1,337,900.00View SEC Filing  
9/25/2015Michael Patrick MillerSVPSell100$145.23$14,523.00View SEC Filing  
9/8/2015Bruce C. CozaddCEOSell2,500$163.07$407,675.00View SEC Filing  
9/1/2015Patrick G EnrightDirectorSell10,000$165.99$1,659,900.00View SEC Filing  
7/14/2015Bruce C CozaddCEOSell5,000$177.79$888,950.00View SEC Filing  
7/14/2015Suzanne Sawochka HooperEVPSell4,000$177.79$711,160.00View SEC Filing  
7/6/2015Patrick G EnrightDirectorSell10,000$177.11$1,771,100.00View SEC Filing  
6/9/2015Bruce C CozaddCEOSell5,000$173.16$865,800.00View SEC Filing  
6/9/2015Suzanne Sawochka HooperEVPSell4,000$173.16$692,640.00View SEC Filing  
6/2/2015Karen J WilsonSVPSell5,751$179.59$1,032,822.09View SEC Filing  
6/1/2015Karen J WilsonSVPSell5,494$179.57$986,557.58View SEC Filing  
4/14/2015Bruce C CozaddCEOSell5,000$181.45$907,250.00View SEC Filing  
4/14/2015Suzanne Sawochka HooperEVPSell4,000$181.45$725,800.00View SEC Filing  
3/25/2015Seamus MulliganDirectorSell50,000$174.59$8,729,500.00View SEC Filing  
1/5/2015Patrick G EnrightDirectorSell10,000$160.25$1,602,500.00View SEC Filing  
12/26/2014Seamus MulliganDirectorSell50,000$163.40$8,170,000.00View SEC Filing  
12/12/2014Patrick G EnrightDirectorSell2,343$170.98$400,606.14View SEC Filing  
12/9/2014Bruce C CozaddCEOSell5,000$178.79$893,950.00View SEC Filing  
12/9/2014Suzanne Sawochka HooperEVPSell1,852$178.79$331,119.08View SEC Filing  
12/1/2014Patrick G EnrightDirectorSell10,000$172.74$1,727,400.00View SEC Filing  
11/24/2014Jeffrey K TobiasCMOSell4,598$170.12$782,211.76View SEC Filing  
11/7/2014Iain McgillSVPSell7,066$172.03$1,215,563.98View SEC Filing  
10/10/2014Jeffrey K TobiasCMOSell1,000$154.04$154,040.00View SEC Filing  
10/6/2014Patrick G EnrightDirectorSell10,000$160.56$1,605,600.00View SEC Filing  
9/25/2014Seamus MulliganDirectorSell50,000$163.16$8,158,000.00View SEC Filing  
9/24/2014Seamus MulliganDirectorSell35,294$163.70$5,777,627.80View SEC Filing  
9/12/2014Jeffrey K TobiasCMOSell1,000$171.22$171,220.00View SEC Filing  
9/11/2014Karen J WilsonSVPSell3,000$175.00$525,000.00View SEC Filing  
9/11/2014Seamus MulliganDirectorSell50,000$175.00$8,750,000.00View SEC Filing  
9/9/2014Bruce C CozaddCEOSell5,000$170.32$851,600.00View SEC Filing  
9/8/2014Karen J WilsonSVPSell2,500$170.00$425,000.00View SEC Filing  
9/8/2014Suzanne Sawochka HooperEVPSell1,852$168.00$311,136.00View SEC Filing  
8/12/2014Bruce C CozaddCEOSell5,000$133.15$665,750.00View SEC Filing  
8/12/2014Suzanne Sawochka HooperEVPSell1,185$133.15$157,782.75View SEC Filing  
8/11/2014Jeffrey K TobiasCMOSell4,933$135.42$668,026.86View SEC Filing  
7/8/2014Bruce C CozaddCEOSell5,000$155.00$775,000.00View SEC Filing  
7/8/2014Suzanne Sawochka HooperEVPSell1,853$155.00$287,215.00View SEC Filing  
7/7/2014Karen J WilsonSVPSell2,500$165.00$412,500.00View SEC Filing  
6/25/2014Seamus MulliganDirectorSell50,000$149.69$7,484,500.00View SEC Filing  
6/20/2014Russell J CoxCOOSell2,000$155.00$310,000.00View SEC Filing  
6/17/2014Fintan KeeganEVPSell3,750$150.00$562,500.00View SEC Filing  
6/10/2014Bruce C CozaddCEOSell5,000$142.34$711,700.00View SEC Filing  
5/16/2014Jeffrey TobiasCMOSell1,000$128.01$128,010.00View SEC Filing  
5/13/2014Bruce CozaddCEOSell5,000$128.92$644,600.00View SEC Filing  
4/17/2014Rick WinninghamDirectorSell27,500$140.00$3,850,000.00View SEC Filing  
4/14/2014Jeffrey TobiasCMOSell3,000$128.54$385,620.00View SEC Filing  
4/8/2014Bruce CozaddCEOSell5,000$123.18$615,900.00View SEC Filing  
3/10/2014Jeffrey TobiasCMOSell3,000$152.99$458,970.00View SEC Filing  
3/6/2014Fintan KeeganEVPSell4,640$159.90$741,936.00View SEC Filing  
3/4/2014Seamus MulliganDirectorSell550,000$156.25$85,937,500.00View SEC Filing  
3/3/2014Patrick EnrightDirectorSell559,628$152.39$85,281,710.92View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Latest Headlines for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Source:
DateHeadline
streetinsider.com logoJazz Pharmaceuticals (JAZZ) to Offer $500M of Exchangeable Senior Notes due 2024
www.streetinsider.com - August 18 at 6:03 AM
finance.yahoo.com logoJazz Pharmaceuticals Announces Offering of $500 Million of Exchangeable Senior Notes due 2024
finance.yahoo.com - August 18 at 6:03 AM
americanbankingnews.com logoInsider Selling: Jazz Pharmaceuticals plc - (JAZZ) EVP Sells 200 Shares of Stock
www.americanbankingnews.com - August 16 at 10:44 PM
americanbankingnews.com logoPaul Treacy Sells 1,304 Shares of Jazz Pharmaceuticals PLC (JAZZ) Stock
www.americanbankingnews.com - August 15 at 7:38 PM
americanbankingnews.com logoJazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Sells $94,248.94 in Stock
www.americanbankingnews.com - August 14 at 11:48 PM
americanbankingnews.com logoJazz Pharmaceuticals PLC (NASDAQ:JAZZ) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - August 12 at 10:32 PM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
finance.yahoo.com - August 12 at 7:03 PM
nasdaq.com logoOversold Conditions For Jazz Pharmaceuticals (JAZZ) - Nasdaq
www.nasdaq.com - August 9 at 9:33 PM
americanbankingnews.com logoJazz Pharmaceuticals PLC (JAZZ) Given a $175.00 Price Target at Deutsche Bank AG
www.americanbankingnews.com - August 9 at 1:30 PM
americanbankingnews.com logoQ3 2017 EPS Estimates for Jazz Pharmaceuticals PLC (JAZZ) Raised by Analyst
www.americanbankingnews.com - August 9 at 7:46 AM
finance.yahoo.com logoEdited Transcript of JAZZ earnings conference call or presentation 8-Aug-17 8:30pm GMT
finance.yahoo.com - August 9 at 5:53 AM
seekingalpha.com logoJazz Pharmaceuticals Plc (JAZZ) Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 9 at 12:52 AM
marketwatch.com logoJazz Pharmaceuticals shares fall after results miss Street estimates - MarketWatch
www.marketwatch.com - August 8 at 7:47 PM
finance.yahoo.com logoJazz Pharmaceuticals Announces Second Quarter 2017 Financial Results
finance.yahoo.com - August 8 at 7:47 PM
finance.yahoo.com logoJazz Pharmaceuticals shares fall after results miss Street estimates
finance.yahoo.com - August 8 at 7:47 PM
finance.yahoo.com logoJazz misses Street 2Q forecasts
finance.yahoo.com - August 8 at 7:47 PM
americanbankingnews.com logoJazz Pharmaceuticals PLC (NASDAQ:JAZZ) Issues FY17 Earnings Guidance
www.americanbankingnews.com - August 8 at 5:58 PM
americanbankingnews.com logoJazz Pharmaceuticals PLC (NASDAQ:JAZZ) Announces Quarterly Earnings Results, Misses Estimates By $0.19 EPS
www.americanbankingnews.com - August 8 at 5:58 PM
benzinga.com logoEarnings Scheduled For August 8, 2017 - Benzinga
www.benzinga.com - August 8 at 5:35 AM
prnewswire.com logoJazz Pharmaceuticals Announces FDA Approval of Vyxeos™ (daunorubicin and cytarabine) Liposome for Injection for ... - PR Newswire (press release)
www.prnewswire.com - August 5 at 11:52 PM
prnewswire.com logoJazz Pharmaceuticals Announces Webcast for Vyxeos Investor Update - PR Newswire (press release)
www.prnewswire.com - August 5 at 3:39 AM
americanbankingnews.com logoZacks: Brokerages Expect Jazz Pharmaceuticals PLC (JAZZ) Will Announce Quarterly Sales of $408.14 Million
www.americanbankingnews.com - August 4 at 9:40 AM
reuters.com logoBRIEF-Jazz Pharmaceuticals announces FDA approval of Vyxeos
www.reuters.com - August 3 at 8:12 PM
finance.yahoo.com logoJazz Pharmaceuticals Announces FDA Approval of Vyxeos™ (daunorubicin and cytarabine) Liposome for Injection for the Treatment of Adults with Newly-Diagnosed Therapy-Related Acute Myeloid Leukemia (t-AML) or AML with Myelodysplasia-Related Changes (AML-MRC)
finance.yahoo.com - August 3 at 8:12 PM
finance.yahoo.com logoJazz Pharmaceuticals Announces Webcast for Vyxeos Investor Update
finance.yahoo.com - August 3 at 8:12 PM
finance.yahoo.com logoDrug developer jazzed to receive FDA approval for leukemia treatment
finance.yahoo.com - August 3 at 8:12 PM
finance.yahoo.com logoCan Jazz Pharma (JAZZ) Spring a Surprise in Q2 Earnings?
finance.yahoo.com - August 3 at 8:12 PM
americanbankingnews.com logo$1.85 EPS Expected for Jazz Pharmaceuticals PLC (JAZZ) This Quarter
www.americanbankingnews.com - August 2 at 7:18 AM
finance.yahoo.com logoJazz Pharmaceuticals Plc breached its 50 day moving average in a Bearish Manner : JAZZ-US : August 1, 2017
finance.yahoo.com - August 2 at 2:43 AM
americanbankingnews.com logoJazz Pharmaceuticals PLC (JAZZ) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - August 1 at 9:26 AM
streetinsider.com logoJazz Pharmaceuticals (JAZZ), XL-protein GmbH Enter Pact on PASylation Technology to Develop Long-Acting Asparaginase Product Candidates
www.streetinsider.com - July 27 at 11:40 PM
prnewswire.com logoJazz Pharmaceuticals and XL-protein GmbH Enter Into a License Agreement on PASylation® Technology to Develop ... - PR Newswire (press release)
www.prnewswire.com - July 26 at 8:27 PM
finance.yahoo.com logoJazz Pharmaceuticals and XL-protein GmbH Enter Into a License Agreement on PASylation® Technology to Develop Long-Acting Asparaginase Product Candidates
finance.yahoo.com - July 26 at 8:27 PM
prnewswire.com logoJazz Pharmaceuticals to Report 2017 Second Quarter Financial Results on August 8, 2017 - PR Newswire (press release)
www.prnewswire.com - July 25 at 9:02 PM
finance.yahoo.com logoJazz Pharmaceuticals to Report 2017 Second Quarter Financial Results on August 8, 2017
finance.yahoo.com - July 25 at 12:40 AM
finance.yahoo.com logoETFs with exposure to Jazz Pharmaceuticals Plc : July 24, 2017
finance.yahoo.com - July 25 at 12:40 AM
nasdaq.com logoBridges Investment Management Inc Buys Bristol-Myers Squibb Company, Bristol-Myers Squibb ...
www.nasdaq.com - July 22 at 11:09 PM
americanbankingnews.com logoSuzanne Sawochka Hooper Sells 4,580 Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Stock
www.americanbankingnews.com - July 21 at 7:30 PM
americanbankingnews.com logoJazz Pharmaceuticals PLC (NASDAQ:JAZZ) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 18 at 10:34 PM
americanbankingnews.com logoJazz Pharmaceuticals PLC (JAZZ) EVP Sells $30,994.00 in Stock
www.americanbankingnews.com - July 18 at 7:53 PM
americanbankingnews.com logoLipoScience (LPDX) and Jazz Pharmaceuticals PLC (JAZZ) Critical Contrast
www.americanbankingnews.com - July 18 at 6:10 PM
americanbankingnews.com logoDeutsche Bank AG Increases Jazz Pharmaceuticals PLC (JAZZ) Price Target to $178.00
www.americanbankingnews.com - July 17 at 7:14 PM
americanbankingnews.com logoJazz Pharmaceuticals PLC (JAZZ) Stock Rating Reaffirmed by Piper Jaffray Companies
www.americanbankingnews.com - July 15 at 9:44 AM
americanbankingnews.com logoJazz Pharmaceuticals PLC (NASDAQ:JAZZ) Given "Buy" Rating at Cowen and Company
www.americanbankingnews.com - July 15 at 8:14 AM
finance.yahoo.com logoETFs with exposure to Jazz Pharmaceuticals Plc : July 14, 2017
finance.yahoo.com - July 15 at 3:23 AM
finance.yahoo.com logoJazz Pharmaceuticals Plc – Value Analysis (NASDAQ:JAZZ) : July 12, 2017
finance.yahoo.com - July 13 at 4:14 AM
americanbankingnews.com logoJazz Pharmaceuticals PLC (JAZZ) Expected to Post Quarterly Sales of $408.14 Million
www.americanbankingnews.com - July 12 at 9:36 AM
seekingalpha.com logoWhat Lies Ahead For Pharma ETFs In Second Half 2017
seekingalpha.com - July 12 at 12:18 AM
finance.yahoo.com logoJazz Pharmaceuticals Plc breached its 50 day moving average in a Bearish Manner : JAZZ-US : July 11, 2017
finance.yahoo.com - July 12 at 12:18 AM
americanbankingnews.com logoZacks: Analysts Expect Jazz Pharmaceuticals PLC (JAZZ) Will Announce Earnings of $1.85 Per Share
www.americanbankingnews.com - July 10 at 8:10 PM

Social

Chart

Jazz Pharmaceuticals PLC (JAZZ) Chart for Friday, August, 18, 2017

This page was last updated on 8/18/2017 by MarketBeat.com Staff